BACKGROUND: The increasing incidence of diabetes mellitus will result in a new epidemic of heart failure unless novel treatments able to halt diabetic cardiomyopathy early in its course are introduced. This study aimed to determine whether the activity of the Akt/Pim-1 signaling pathway is altered at critical stages of diabetic cardiomyopathy and whether supplementation with vitamin B1 analog benfotiamine (BFT) helps to sustain the above prosurvival mechanism, thereby preserving cardiomyocyte viability and function. METHODS AND RESULTS: Untreated streptozotocin-induced type 1 or leptin-receptor mutant type 2 diabetic mice showed diastolic dysfunction evolving to contractile impairment and cardiac dilatation and failure. BFT (70 mg/kg(-1)/d(-1)) improved diastolic and systolic function and prevented left ventricular end-diastolic pressure increase and chamber dilatation in both diabetic models. Moreover, BFT improved cardiac perfusion and reduced cardiomyocyte apoptosis and interstitial fibrosis. In hearts of untreated diabetic mice, the expression and activity of Akt/Pim-1 signaling declined along with O-N-acetylglucosamine modification of Akt, inhibition of pentose phosphate pathway, activation of oxidative stress, and accumulation of glycation end products. Furthermore, diabetes reduced pSTAT3 independently of Akt. BFT inhibited these effects of diabetes mellitus, thereby conferring cardiomyocytes with improved resistance to high glucose-induced damage. The phosphoinositide-3-kinase inhibitor LY294002 and dominant-negative Akt inhibited antiapoptotic action of BFT-induced and Pim-1 upregulation in high glucose-challenged cardiomyocytes. CONCLUSIONS: These results show that BFT protects from diabetes mellitus-induced cardiac dysfunction through pleiotropic mechanisms, culminating in the activation of prosurvival signaling pathway. Thus, BFT merits attention for application in clinical practice.
BACKGROUND: The increasing incidence of diabetes mellitus will result in a new epidemic of heart failure unless novel treatments able to halt diabetic cardiomyopathy early in its course are introduced. This study aimed to determine whether the activity of the Akt/Pim-1 signaling pathway is altered at critical stages of diabetic cardiomyopathy and whether supplementation with vitamin B1 analog benfotiamine (BFT) helps to sustain the above prosurvival mechanism, thereby preserving cardiomyocyte viability and function. METHODS AND RESULTS: Untreated streptozotocin-induced type 1 or leptin-receptor mutant type 2 diabeticmice showed diastolic dysfunction evolving to contractile impairment and cardiac dilatation and failure. BFT (70 mg/kg(-1)/d(-1)) improved diastolic and systolic function and prevented left ventricular end-diastolic pressure increase and chamber dilatation in both diabetic models. Moreover, BFT improved cardiac perfusion and reduced cardiomyocyte apoptosis and interstitial fibrosis. In hearts of untreated diabeticmice, the expression and activity of Akt/Pim-1 signaling declined along with O-N-acetylglucosamine modification of Akt, inhibition of pentose phosphate pathway, activation of oxidative stress, and accumulation of glycation end products. Furthermore, diabetes reduced pSTAT3 independently of Akt. BFT inhibited these effects of diabetes mellitus, thereby conferring cardiomyocytes with improved resistance to high glucose-induced damage. The phosphoinositide-3-kinase inhibitor LY294002 and dominant-negative Akt inhibited antiapoptotic action of BFT-induced and Pim-1 upregulation in high glucose-challenged cardiomyocytes. CONCLUSIONS: These results show that BFT protects from diabetes mellitus-induced cardiac dysfunction through pleiotropic mechanisms, culminating in the activation of prosurvival signaling pathway. Thus, BFT merits attention for application in clinical practice.
Authors: S Gadau; C Emanueli; S Van Linthout; G Graiani; M Todaro; M Meloni; I Campesi; G Invernici; F Spillmann; K Ward; P Madeddu Journal: Diabetologia Date: 2006-01-17 Impact factor: 10.122
Authors: Tomohisa Nagoshi; Takashi Matsui; Takuma Aoyama; Annarosa Leri; Piero Anversa; Ling Li; Wataru Ogawa; Federica del Monte; Judith K Gwathmey; Luanda Grazette; Brian A Hemmings; Brian Hemmings; David A Kass; Hunter C Champion; Anthony Rosenzweig Journal: J Clin Invest Date: 2005-07-07 Impact factor: 14.808
Authors: Rob D Catalano; Martin H Johnson; Elizabeth A Campbell; D Stephen Charnock-Jones; Stephen K Smith; Andrew M Sharkey Journal: Proc Natl Acad Sci U S A Date: 2005-06-03 Impact factor: 11.205
Authors: Zi-Lun Li; John R Woollard; Behzad Ebrahimi; John A Crane; Kyra L Jordan; Amir Lerman; Shen-Ming Wang; Lilach O Lerman Journal: Arterioscler Thromb Vasc Biol Date: 2012-03-01 Impact factor: 8.311
Authors: Marco Meloni; Andrea Caporali; Gallia Graiani; Costanza Lagrasta; Rajesh Katare; Sophie Van Linthout; Frank Spillmann; Ilaria Campesi; Paolo Madeddu; Federico Quaini; Costanza Emanueli Journal: Circ Res Date: 2010-04-01 Impact factor: 17.367
Authors: Andreas W Schoenenberger; Renate Schoenenberger-Berzins; Christoph Auf der Maur; Paolo M Suter; Athanasios Vergopoulos; Paul Erne Journal: Clin Res Cardiol Date: 2011-11-05 Impact factor: 5.460
Authors: Peter A Hecker; Jane A Leopold; Sachin A Gupte; Fabio A Recchia; William C Stanley Journal: Am J Physiol Heart Circ Physiol Date: 2012-12-15 Impact factor: 4.733